Departments of Breast and Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Eur J Dermatol. 2011 Jul-Aug;21(4):539-45. doi: 10.1684/ejd.2011.1403.
The purpose of this study was to evaluate the efficacy of taxane regimens in patients with metastatic angiosarcoma. Forty-one patients with metastatic angiosarcoma treated at the National Cancer Center Hospital between January 1982 and January 2009 were retrospectively classified into 3 groups according to the treatment type: (i) taxane (n=11), (ii) non-taxane (n=14), and (iii) best supportive care (BSC; n=16) groups. The taxane group received paclitaxel (n=6), docetaxel (n=4), or albumin-bound paclitaxel (n=1), and the non-taxane group received mainly doxorubicin-containing regimens (n=12). The differences in progression-free survival (PFS) among the 3 groups were statistically significant (P<0.001). After adjusting for prognostic factors, the taxane group had significantly longer PFS than the non-taxane (hazard ratio=0.282; 95% confidence interval=0.086-0.923; P=0.036) and BSC (hazard ratio=0.015; 95% confidence interval = 0.003-0.083; P<0.001) groups. Overall survival was also significantly longer in the taxane group than in the other groups. A taxane regimen may be more effective than a non-taxane regimen for treating patients with metastatic angiosarcoma.
本研究旨在评估紫杉烷类方案在转移性血管肉瘤患者中的疗效。1982 年 1 月至 2009 年 1 月期间，国家癌症中心医院共收治 41 例转移性血管肉瘤患者，根据治疗类型将其分为 3 组：（i）紫杉烷组（n=11）、（ii）非紫杉烷组（n=14）和（iii）最佳支持治疗（BSC；n=16）组。紫杉烷组接受紫杉醇（n=6）、多西他赛（n=4）或白蛋白结合紫杉醇（n=1）治疗，非紫杉烷组主要接受多柔比星类方案治疗（n=12）。3 组间无进展生存期（PFS）的差异具有统计学意义（P<0.001）。调整预后因素后，紫杉烷组 PFS 明显长于非紫杉烷组（风险比=0.282；95%置信区间=0.086-0.923；P=0.036）和 BSC 组（风险比=0.015；95%置信区间=0.003-0.083；P<0.001）。紫杉烷组的总生存期也明显长于其他两组。紫杉烷类方案可能比非紫杉烷类方案更有效治疗转移性血管肉瘤患者。
